Back to search results

Observational Study for Malignant Diseases

This observational study is collecting blood and tissue samples from people with, or suspected of having, malignant diseases (cancers) like kidney or bladder cancer, or inherited conditions that increase cancer risk. The goal is to understand the genetic and molecular causes of these cancers, including how new blood vessels form (angiogenesis), and how cancer cells respond to treatments. This information will help researchers develop new therapies. You can join if you are at least 2 years old and have a confirmed or suspected malignant disease, or if you are a blood relative of someone with such a diagnosis. The study is ongoing and aims to enroll nearly 6000 participants.

Study design
This is an observational study with no specified phase, planning to enroll 5950 participants. It is collecting samples to understand cancer.
What's involved
You may have blood samples collected at your initial visit and periodically during your disease course. If you have surgery, malignant and normal tissue samples may also be collected.
Compensation
Not stated in the trial record.
Follow-up
The study is investigating quality of life, molecular genetics, and cellular responses on an ongoing basis.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT00026884

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

Recruiting
Not specifiedAges 2+Observational
National Cancer Institute (NCI)
~5,950 participants
Updated 2026-08-28 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Investigate quality of life in men who have prostate cancer.
Measured over on-going
+6 more outcomes measured

Conditions

Malignant Neoplasms
Hereditary Neoplastic Syndromes
Kidney Cancer
Renal Cancer
Bladder Cancer

Explore related trials

Bladder CarcinomaHereditary Neoplastic SyndromeKidney CarcinomaMalignant Neoplasm

Where it's being run

1 sites across 1 states
Maryland1

Study leadership

  • W. Marston Linehan, M.D. · PRINCIPAL_INVESTIGATOR · National Cancer Institute (NCI)

Who to contact

Deborah A Nielsen, R.N.
[email protected]
(240) 760-6247
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Individuals with biopsy-proven malignant disease
Individuals suspected of having a malignant disease
Individuals who have or are suspected of having an inherited genitourinary malignant disorder
Participants must be \>= 2 years of age
A relative (related by blood) of an individual with a confirmed or suspected diagnosis of a malignant disease or an inherited genitourinary malignant disorder.
All participants and parents/guardians, for children younger than 18 years of age, must sign an informed consent document indicating their understanding of the investigational nature and the risks of this study before any protocol related studies are performed.

Exclusion

Individuals whose co-morbidities preclude surgical intervention.

What this trial measures

  • Investigate quality of life in men who have prostate cancer.on-going

    Prostate cancer participants that have improvement in quality of life

  • Investigate molecular genetic basis of urologic malignancieson-going

    Investigate molecular genetic basis of urologic malignancies

  • Investigate cellular/biochemical response to existing and novel therapeutic agents.on-going

    Collection of blood, urine, saliva, and/or benign and malignant tissue

  • Examine protein expression and bioimmunoassays investigating potential genetic markers.on-going

    Detection and expression analysis of gene(s)

  • Determine the molecular genetic differences between normal and tumorigenic tissues.on-going

    Molecular genetic differences between normal and tumorigenic tissues

  • Collection of benign and malignant tissue from individuals with rare inherited conditions associated with an increased risk for kidney cancer.on-going

    Collection of blood, urine, saliva, and/or benign and malignant tissue

  • Collection of benign and malignant tissue from individuals with known or suspected cancer.on-going

    Collection of blood, urine, saliva, and/or benign and malignant tissue